Novavax, Inc.

Novavax, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Novavax, Inc. could be a weak company given it's low Piotroski F-score. Novavax, Inc. is not a good value stock. Novavax, Inc. is not very popular among insiders. Novavax, Inc. is a mediocre stock to choose.
Log in to see more information.
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and...
NVAX Fundamental Data by TradingView

News

Why Are Novavax Shares Trading Lower Today?
Why Are Novavax Shares Trading Lower Today?

Benzinga Novavax Inc. (NASDAQ: NVAX) shares are trading lower Thursday following multiple significant announcements. Here's what you need to know.\n more…

Quest Partners LLC Buys New Position in Novavax, Inc. (NASDAQ:NVAX)
Quest Partners LLC Buys New Position in Novavax, Inc. (NASDAQ:NVAX)

Zolmax Quest Partners LLC bought a new stake in Novavax, Inc. (NASDAQ:NVAX - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange...\n more…

Novavax, Inc. (NASDAQ:NVAX) Shares Acquired by Bank of New York Mellon Corp
Novavax, Inc. (NASDAQ:NVAX) Shares Acquired by Bank of New York Mellon Corp

Ticker Report Bank of New York Mellon Corp boosted its holdings in Novavax, Inc. (NASDAQ:NVAX - Free Report) by 34.3% in the second quarter, according to its most recent disclosure with the Securities &...\n more…

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Zacks Investment Research Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over...\n more…

Could This Be the Catalyst Novavax Needs to Get Its Stock Rallying Again?
Could This Be the Catalyst Novavax Needs to Get Its Stock Rallying Again?

Fool.com Headlines Struggling biotech Novavax (NASDAQ: NVAX) was a hot buy a few years ago as it was in the midst of developing a vaccine for COVID-19. Ultimately, it did produce an approved vaccine, but it was a bit...\n more…

There Are 3 New COVID Vaccines, but the Way You Pay for Them Has Changed. What to Know
There Are 3 New COVID Vaccines, but the Way You Pay for Them Has Changed. What to Know

CNET News The FDA has authorized Novavax's new formula, adding to a repertoire of revamped COVID vaccines. Here's what to know about cost and more.\n more…